Search - tctmd.com

Displaying 201 - 220 of 400

Sort: Relevancy | Date

Presentation JIM 2018

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Presenter: Roxana Mehran

February 23, 2018

Presentation TTT 2018

Use of NOAC in Coronary Artery Disease

Presenter: Tsung-Hsien Lin

January 14, 2018

Presentation AHA 2017

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Presenter: Akihiko Nogami

November 13, 2017

Presentation TCT 2017

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation

Presenter: Saibal Kar

November 02, 2017

Presentation TCT 2017

Case #2 Resolution: How We Treated a High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Complex Multi-stent PCI or Any PCI for ACS

Presenter: Renato D. Lopes, David J. Moliterno, Sheila Sahni

November 01, 2017

Presentation TCT 2017

Case #2 Introduction: High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Complex Multi-stent PCI or Any PCI for ACS

Presenter: Renato D. Lopes, David J. Moliterno, Sheila Sahni

November 01, 2017

Presentation TCT 2017

Case #1 Resolution: How We Treated a High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Non-Complex PCI for Stable CAD

Presenter: Renato D. Lopes, David J. Moliterno, Amit N Vora

November 01, 2017

Presentation TCT 2017

Case #1 Introduction: High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Non-Complex PCI for Stable CAD

Presenter: Renato D. Lopes, David J. Moliterno, Amit N Vora

November 01, 2017

Presentation TCT 2017

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Samir R. Kapadia, Ioanna Kosmidou

November 01, 2017

Presentation TCT 2017

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Samir R. Kapadia, David J. Moliterno

November 01, 2017

Presentation TCT 2017

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Samir R. Kapadia, Sameer Gafoor

November 01, 2017

Presentation TCT 2017

PIONEER AF: Topline Findings and Practice Implications

Presenter: Robert A. Harrington, Evan A. Stein, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

Is LAA Closure an Alternative to Triple Therapy for All Patients or Just Those at High Bleeding Risk? Current Dataset

Presenter: Samir R. Kapadia, Brian K. Whisenant

November 01, 2017

Presentation TCT 2017

Rationale and Potential Role for LAA Closure in the PCI and ACS Patient

Presenter: Samir R. Kapadia, Ashish Pershad

November 01, 2017

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2017

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

Presenter: Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Presenter: Robert A. Harrington, Kurt Huber, Michael D. Ezekowitz

November 01, 2017

Advertisement

Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing PCI: "Dual Therapy is the right choice”

Use of NOAC in Coronary Artery Disease

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation

Case #2 Resolution: How We Treated a High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Complex Multi-stent PCI or Any PCI for ACS

Case #2 Introduction: High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Complex Multi-stent PCI or Any PCI for ACS

Case #1 Resolution: How We Treated a High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Non-Complex PCI for Stable CAD

Case #1 Introduction: High Bleeding-Risk Patient With Chronic Atrial Fibrillation Undergoing Non-Complex PCI for Stable CAD

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

PIONEER AF: Topline Findings and Practice Implications

Is LAA Closure an Alternative to Triple Therapy for All Patients or Just Those at High Bleeding Risk? Current Dataset

Rationale and Potential Role for LAA Closure in the PCI and ACS Patient

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content